Cargando…

PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation

PURPOSE: The inhibition of immune checkpoints such as programmed cell death ligand-1 (PD-L1/CD274) with antibodies is providing novel opportunities to expose cancer cells to the immune system. Antibody based checkpoint blockade can, however, result in serious autoimmune complications because normal...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacheco-Torres, Jesus, Penet, Marie-France, Krishnamachary, Balaji, Mironchik, Yelena, Chen, Zhihang, Bhujwalla, Zaver M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947807/
https://www.ncbi.nlm.nih.gov/pubmed/33718115
http://dx.doi.org/10.3389/fonc.2020.614365
_version_ 1783663304652095488
author Pacheco-Torres, Jesus
Penet, Marie-France
Krishnamachary, Balaji
Mironchik, Yelena
Chen, Zhihang
Bhujwalla, Zaver M.
author_facet Pacheco-Torres, Jesus
Penet, Marie-France
Krishnamachary, Balaji
Mironchik, Yelena
Chen, Zhihang
Bhujwalla, Zaver M.
author_sort Pacheco-Torres, Jesus
collection PubMed
description PURPOSE: The inhibition of immune checkpoints such as programmed cell death ligand-1 (PD-L1/CD274) with antibodies is providing novel opportunities to expose cancer cells to the immune system. Antibody based checkpoint blockade can, however, result in serious autoimmune complications because normal tissues also express immune checkpoints. As sequence-specific gene-silencing agents, the availability of siRNA has significantly expanded the specificity and range of “druggable” targets making them promising agents for precision medicine in cancer. Here, we have demonstrated the ability of a novel biodegradable dextran based theranostic nanoparticle (NP) to deliver siRNA downregulating PD-L1 in tumors. Optical imaging highlighted the importance of NP delivery and accumulation in tumors to achieve effective downregulation with siRNA NPs, and demonstrated low delivery and accumulation in several PD-L1 expressing normal tissues. METHODS: The dextran scaffold was functionalized with small molecules containing amine groups through acetal bonds. The NP was decorated with a Cy5.5 NIR probe allowing visualization of NP delivery, accumulation, and biodistribution. MDA-MB-231 triple negative human breast cancer cells were inoculated orthotopically or subcutaneously to achieve differences in vascular delivery in the tumors. Molecular characterization of PD-L1 mRNA and protein expression in cancer cells and tumors was performed with qRT-PCR and immunoblot analysis. RESULTS: The PD-L1 siRNA dextran NPs effectively downregulated PD-L1 in MDA-MB-231 cells. We identified a significant correlation between NP delivery and accumulation, and the extent of PD-L1 downregulation, with in vivo imaging. The size of the NP of ~ 20 nm allowed delivery through leaky tumor vasculature but not through the vasculature of high PD-L1 expressing normal tissue such as the spleen and lungs. CONCLUSIONS: Here we have demonstrated, for the first time, the feasibility of downregulating PD-L1 in tumors using siRNA delivered with a biodegradable dextran polymer that was decorated with an imaging reporter. Our data demonstrate the importance of tumor NP delivery and accumulation in achieving effective downregulation, highlighting the importance of imaging in siRNA NP delivery. Effective delivery of these siRNA carrying NPs in the tumor but not in normal tissues may mitigate some of the side-effects of immune checkpoint inhibitors by sparing PD-L1 inhibition in these tissues.
format Online
Article
Text
id pubmed-7947807
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79478072021-03-12 PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation Pacheco-Torres, Jesus Penet, Marie-France Krishnamachary, Balaji Mironchik, Yelena Chen, Zhihang Bhujwalla, Zaver M. Front Oncol Oncology PURPOSE: The inhibition of immune checkpoints such as programmed cell death ligand-1 (PD-L1/CD274) with antibodies is providing novel opportunities to expose cancer cells to the immune system. Antibody based checkpoint blockade can, however, result in serious autoimmune complications because normal tissues also express immune checkpoints. As sequence-specific gene-silencing agents, the availability of siRNA has significantly expanded the specificity and range of “druggable” targets making them promising agents for precision medicine in cancer. Here, we have demonstrated the ability of a novel biodegradable dextran based theranostic nanoparticle (NP) to deliver siRNA downregulating PD-L1 in tumors. Optical imaging highlighted the importance of NP delivery and accumulation in tumors to achieve effective downregulation with siRNA NPs, and demonstrated low delivery and accumulation in several PD-L1 expressing normal tissues. METHODS: The dextran scaffold was functionalized with small molecules containing amine groups through acetal bonds. The NP was decorated with a Cy5.5 NIR probe allowing visualization of NP delivery, accumulation, and biodistribution. MDA-MB-231 triple negative human breast cancer cells were inoculated orthotopically or subcutaneously to achieve differences in vascular delivery in the tumors. Molecular characterization of PD-L1 mRNA and protein expression in cancer cells and tumors was performed with qRT-PCR and immunoblot analysis. RESULTS: The PD-L1 siRNA dextran NPs effectively downregulated PD-L1 in MDA-MB-231 cells. We identified a significant correlation between NP delivery and accumulation, and the extent of PD-L1 downregulation, with in vivo imaging. The size of the NP of ~ 20 nm allowed delivery through leaky tumor vasculature but not through the vasculature of high PD-L1 expressing normal tissue such as the spleen and lungs. CONCLUSIONS: Here we have demonstrated, for the first time, the feasibility of downregulating PD-L1 in tumors using siRNA delivered with a biodegradable dextran polymer that was decorated with an imaging reporter. Our data demonstrate the importance of tumor NP delivery and accumulation in achieving effective downregulation, highlighting the importance of imaging in siRNA NP delivery. Effective delivery of these siRNA carrying NPs in the tumor but not in normal tissues may mitigate some of the side-effects of immune checkpoint inhibitors by sparing PD-L1 inhibition in these tissues. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7947807/ /pubmed/33718115 http://dx.doi.org/10.3389/fonc.2020.614365 Text en Copyright © 2021 Pacheco-Torres, Penet, Krishnamachary, Mironchik, Chen and Bhujwalla http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Pacheco-Torres, Jesus
Penet, Marie-France
Krishnamachary, Balaji
Mironchik, Yelena
Chen, Zhihang
Bhujwalla, Zaver M.
PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation
title PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation
title_full PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation
title_fullStr PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation
title_full_unstemmed PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation
title_short PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation
title_sort pd-l1 sirna theranostics with a dextran nanoparticle highlights the importance of nanoparticle delivery for effective tumor pd-l1 downregulation
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947807/
https://www.ncbi.nlm.nih.gov/pubmed/33718115
http://dx.doi.org/10.3389/fonc.2020.614365
work_keys_str_mv AT pachecotorresjesus pdl1sirnatheranosticswithadextrannanoparticlehighlightstheimportanceofnanoparticledeliveryforeffectivetumorpdl1downregulation
AT penetmariefrance pdl1sirnatheranosticswithadextrannanoparticlehighlightstheimportanceofnanoparticledeliveryforeffectivetumorpdl1downregulation
AT krishnamacharybalaji pdl1sirnatheranosticswithadextrannanoparticlehighlightstheimportanceofnanoparticledeliveryforeffectivetumorpdl1downregulation
AT mironchikyelena pdl1sirnatheranosticswithadextrannanoparticlehighlightstheimportanceofnanoparticledeliveryforeffectivetumorpdl1downregulation
AT chenzhihang pdl1sirnatheranosticswithadextrannanoparticlehighlightstheimportanceofnanoparticledeliveryforeffectivetumorpdl1downregulation
AT bhujwallazaverm pdl1sirnatheranosticswithadextrannanoparticlehighlightstheimportanceofnanoparticledeliveryforeffectivetumorpdl1downregulation